PMID- 33691685
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210314
IS  - 1475-2867 (Print)
IS  - 1475-2867 (Electronic)
IS  - 1475-2867 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Mar 10
TI  - Discovery and validation of PZP as a novel serum biomarker for screening lung 
      adenocarcinoma in type 2 diabetes mellitus patients.
PG  - 162
LID - 10.1186/s12935-021-01861-8 [doi]
LID - 162
AB  - BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) have an increased risk 
      of suffering from various malignancies. This study aimed to identify specific 
      biomarkers that can detect lung adenocarcinoma (LAC) in T2DM patients for the 
      early diagnosis of LAC. METHODS: The clinical information of hospitalized T2DM 
      patients diagnosed with various cancers was collected by reviewing medical 
      records in Wuxi People's Hospital Affiliated to Nanjing Medical University from 
      January 1, 2015, to June 30, 2020. To discover diagnostic biomarkers for 
      early-stage LAC in the T2DM population, 20 samples obtained from 5 healthy 
      controls, 5 T2DM patients, 5 LAC patients and 5 T2DM patients with LAC 
      (T2DM + LAC) were subjected to sequential windowed acquisition of all theoretical 
      fragment ion mass spectrum (SWATH-MS) analysis to identify specific 
      differentially-expressed proteins (DEPs) for LAC in patients with T2DM. Then, 
      these results were validated by parallel reaction monitoring MS (PRM-MS) and 
      ELISA analyses. RESULTS: Lung cancer was the most common malignant tumor in 
      patients with T2DM, and LAC accounted for the majority of cases. Using SWATH-MS 
      analysis, we found 13 proteins to be unique in T2DM patients with early LAC. Two 
      serum proteins were further validated by PRM-MS analysis, namely, pregnancy-zone 
      protein (PZP) and insulin-like growth factor binding protein 3 (IGFBP3). 
      Furthermore, the diagnostic values of these proteins were validated by ELISA, and 
      PZP was validated as a novel serum biomarker for screening LAC in T2DM patients. 
      CONCLUSIONS: Our findings indicated that PZP could be used as a novel serum 
      biomarker for the identification of LAC in T2DM patients, which will enhance 
      auxiliary diagnosis and assist in the selection of surgical treatment at an early 
      stage.
FAU - Yang, Jiayue
AU  - Yang J
AD  - Department of Endocrinology, Wuxi People's Hospital Affiliated to Nanjing Medical 
      University, Wuxi, 214023, China.
FAU - Yang, Cheng
AU  - Yang C
AD  - Department of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing 
      Medical University, Wuxi, 214023, China.
FAU - Shen, Hong
AU  - Shen H
AD  - Department of Endocrinology, Wuxi People's Hospital Affiliated to Nanjing Medical 
      University, Wuxi, 214023, China.
FAU - Wu, Wenjun
AU  - Wu W
AD  - Department of Endocrinology, Wuxi People's Hospital Affiliated to Nanjing Medical 
      University, Wuxi, 214023, China.
FAU - Tian, Zhen
AU  - Tian Z
AD  - Department of Clinical Laboratory, Wuxi People's Hospital Affiliated to Nanjing 
      Medical University, Wuxi, 214023, China.
FAU - Xu, Qinghua
AU  - Xu Q
AD  - Department of Endocrinology, Wuxi People's Hospital Affiliated to Nanjing Medical 
      University, Wuxi, 214023, China.
FAU - Cao, Cuiping
AU  - Cao C
AD  - Department of Endocrinology, Wuxi People's Hospital Affiliated to Nanjing Medical 
      University, Wuxi, 214023, China.
FAU - Ye, Shugao
AU  - Ye S
AD  - Department of Chest Surgery, Wuxi People's Hospital Affiliated to Nanjing Medical 
      University, Wuxi, 214023, China.
FAU - Ban, Le
AU  - Ban L
AD  - Department of Chest Surgery, Wuxi People's Hospital Affiliated to Nanjing Medical 
      University, Wuxi, 214023, China.
FAU - Tong, Xin
AU  - Tong X
AD  - Department of Clinical Laboratory, Wuxi People's Hospital Affiliated to Nanjing 
      Medical University, Wuxi, 214023, China.
FAU - Mei, Jie
AU  - Mei J
AUID- ORCID: 0000-0001-7799-8129
AD  - Department of Oncology, Wuxi People's Hospital Affiliated to Nanjing Medical 
      University, No. 299 Qingyang Road, Wuxi, 214023, China. meijie1996@njmu.edu.cn.
LA  - eng
GR  - M202016/General Project of Wuxi Health Commission/
GR  - Z202017/Major Project of Wuxi Health Commission/
GR  - BJ2020011/Taihu Talent Program/
PT  - Journal Article
DEP - 20210310
PL  - England
TA  - Cancer Cell Int
JT  - Cancer cell international
JID - 101139795
PMC - PMC7945354
OTO - NOTNLM
OT  - Biomarker
OT  - Lung adenocarcinoma
OT  - Mass spectrum
OT  - Type 2 diabetes mellitus
COIS- The authors declare no conflict of interest.
EDAT- 2021/03/12 06:00
MHDA- 2021/03/12 06:01
PMCR- 2021/03/10
CRDT- 2021/03/11 05:48
PHST- 2021/01/24 00:00 [received]
PHST- 2021/03/01 00:00 [accepted]
PHST- 2021/03/11 05:48 [entrez]
PHST- 2021/03/12 06:00 [pubmed]
PHST- 2021/03/12 06:01 [medline]
PHST- 2021/03/10 00:00 [pmc-release]
AID - 10.1186/s12935-021-01861-8 [pii]
AID - 1861 [pii]
AID - 10.1186/s12935-021-01861-8 [doi]
PST - epublish
SO  - Cancer Cell Int. 2021 Mar 10;21(1):162. doi: 10.1186/s12935-021-01861-8.